Bharat Parenterals Peer Comparison

BSE: 541096

₹1,882.80

₹8.60 (0.46%)

As on 14-Oct-2026 11:54IST

Market cap

₹1,300 Cr

Revenue (TTM)

₹323 Cr

P/E Ratio

P/B Ratio

Div. Yield

0.1 %

Edit

	Bharat Parenterals	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Market cap (₹ Cr)	1,300	18,791	17,876	17,933	16,103
Revenue (₹ Cr)	323	1,682	2,287	2,570	3,230
Net Profit (₹ Cr)	-29.99	273.51	678.07	735.15	666.92
Net Margin (%)	-9.01	16.19	28.10	26.88	20.60
RoE (%)	-4.72	11.15	19.73	19.16	18.75
Price to Earnings	--	63.69	26.93	24.39	24.99
Price-To-Book	3.99	7.05	4.88	4.07	3.99

Income Statement (₹ Cr)

	Bharat Parenterals	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Operating Revenue	323.17	1,682.47	2,287.33	2,569.77	3,229.67
Total Income	332.76	1,689.83	2,413.29	2,735.39	3,237.12
Total Expenditure	312.59	1,203.91	1,490.75	1,628.14	2,090.06
EBITDA	10.58	478.55	796.58	941.63	1,139.61
Depreciation	34.33	126.01	78.10	57.58	281.06
EBIT	-23.75	352.55	718.48	884.05	858.55
Interest	11.31	52.11	0.88	7.69	190.64
Other Income	9.60	7.37	125.96	165.62	7.45
Exceptional Items	0.00	12.16	0.00	-49.16	-17.24
Profit before Tax	-25.46	319.96	843.56	992.82	658.12
Provision for Tax	4.53	46.45	165.49	257.67	-8.80
Profit after Tax	-29.99	273.51	678.07	735.15	666.92

	Bharat Parenterals	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Shareholder's Funds	322.23	2,591.20	3,586.42	4,202.90	3,902.67
Minority Interest	14.59	0.00	-12.71	0.00	-21.81
Non-Current Liabilities	144.32	266.35	28.74	91.50	1,392.75
Current Liabilities	157.39	848.06	385.94	627.48	2,077.10
Total Liabilities	620.18	3,705.61	4,037.51	4,921.88	7,246.72

	Bharat Parenterals	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Non-Current Assets	293.10	2,525.44	1,291.22	770.28	5,617.77
Current Assets	310.08	1,109.77	2,585.66	3,803.22	1,539.85
Total Assets	620.18	3,705.61	4,037.51	4,921.88	7,246.72
Total Debt*	146.11	657.97	0.57	2.50	2,309.68
Net Current Assets	152.69	261.71	2,199.72	3,175.74	-537.25
Contingent Liabilities	21.52	160.01	17.53	370.49	51.57

	Bharat Parenterals	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Cash From Operating Activities	38.36	342.18	523.24	967.57	537.99
Cash Flow from Investing Activities	9.32	-325.92	-582.30	-561.67	-369.46
Cash from Financing Activities	-47.05	13.62	-46.46	-798.31	-313.53
Net Cash Inflow / Outflow	0.64	29.88	-105.52	-392.41	-145.00

	Bharat Parenterals	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
ROCE (%)	-1.82	11.43	24.97	23.39	14.47
ROE (%)	-4.72	11.15	19.73	19.16	18.75
ROA (%)	-4.75	7.80	18.69	14.95	9.26
EBIT Margin (%)	-7.35	20.95	31.41	34.40	26.58
Net Margin (%)	-9.01	16.19	28.10	26.88	20.60
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Bharat Parenterals	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Revenue Growth (%)	-11.19	27.91	15.01	10.69	9.59
EBIT Growth (%)	-3.75	58.32	18.45	24.14	16.84
Net Profit Growth (%)	15.99	149.56	19.61	-9.09	62.68
EPS Growth (%)	-152.62	-3.57	17.73	14.40	67.41
Book Value Growth (%)	-2.55	9.67	26.75	-0.34	36.71

	Bharat Parenterals	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Price / Earnings	-84.69	67.94	26.96	24.05	24.15
Price / Book Value	4.09	7.09	4.88	4.21	3.96
Dividend Yield (%)	0.05	0.06	0.34	1.85	0.00
EV/EBITDA	135.49	41.07	21.26	16.40	15.97
Market Cap (₹ Cr)	620.46	6,819.66	11,439.22	21,592.90	17,980.08

	Bharat Parenterals	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debt to Equity	0.38	0.07	0.00	0.00	0.24
Short term debt to equity ratio	0.05	0.16	0.00	0.00	0.12
Current Ratio	1.97	1.31	6.70	6.06	0.74
Quick Ratio	1.43	0.88	5.59	5.31	0.53
Interest Coverage	-1.25	7.14	959.59	130.11	4.45

	Bharat Parenterals	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debtors to sales (%)	46.62	30.84	36.10	7.07	21.07
Asset Turnover	0.51	0.48	0.63	0.52	0.45
Receivable days	170.08	113.81	121.68	26.06	63.88
Inventory Days	82.65	84.76	63.83	65.95	43.27
Payable days	131.69	101.94	108.28	81.01	151.85
Cash Conversion Cycle	121.04	96.62	77.23	11.00	-44.70

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.